The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis

British Journal of Dermatology

Volumn 153, Issue 5, 2005, Pages 869-873

  Warren, R B ^a   Griffiths, C E M ^b  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Folate; Genetics; Methotrexate; Pharmacogenetics; Psoriasis

Indexed keywords

AZATHIOPRINE; FOLIC ACID; FOLINIC ACID; METHOTREXATE; THIOPURINE METHYLTRANSFERASE;

CLINICAL TRIAL; DRUG MECHANISM; DRUG SAFETY; DRUG USE; FOLATE METABOLISM; GENE EXPRESSION; HUMAN; LIVER TOXICITY; PHARMACOGENETICS; PHENOTYPE; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM;

FOLIC ACID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PSORIASIS;

EID: 27544442710     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06880.x     Document Type: Review

References (51)

1. Dicken CH. Treatment of classic pityriasis rubra pilaris. J Am Acad Dermatol 1994; 31:997-9.
2. Fairris GM, White JE, Leppard BJ, Goodwin PG. Methotrexate for intractable benign familial chronic pemphigus. Br J Dermatol 1986; 115:640.
3. Veien NK, Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol 1977; 97:213-16.
4. Metzger AL, Bohan A, Goldberg LS et al. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974; 81:182-9.
5. Bottomley WW, Goodfield MJD. Methotrexate for the treatment of severe mucocutaneous lupus erythematosus. Br J Dermatol 1995; 133:311-14.
6. Gubner R. Effect of aminopterin on epithelial tissues. AMA Arch Derm Syphilol 1951; 64:688-99.
7. Edmundson WF, Guy WB. Treatment of psoriasis with a folic acid antagonist. Arch Dermatol 1958; 78:200-3.
8. Ameen M, Smith CH, Barker JNWN. Pharmacogenetics in clinical dermatology. Br J Dermatol 2002; 146:2-6.
9. van Dooren-Greebe R, Kuijpers A, Mulder J et al. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994; 130:204-10.
10. Shupack JL, Webster GF. Pancytopenia following low-dose oral methotrexate therapy for psoriasis. JAMA 1988; 259:3594-6.
11. Zachariae H, Kragballe K, Sogaard H. Methotrexate induced liver cirrhosis. Br J Dermatol 1980; 102:407-12.
12. Roenigk HH, Auerbach R, Maibach HI et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19:145-56.
13. Ameen M, Taylor DA, Williams IP et al. Pneumonitis complicating methotrexate therapy for pustular psoriasis. J Eur Acad Dermatol Venereol 2001; 15:247-9.
14. Baker H. Intermittent high dose oral methotrexate therapy in psoriasis. Br J Dermatol 1970; 82:65-9.
15. Zonneveld I, Bakker W, Dijkstra P et al. Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol 1996; 132:184-7.
16. Comaish S, Juhlin L. Site of action of methotrexate in psoriasis. Arch Dermatol 1969; 100:99-105.
17. van de Kerkhof PCM, Hoefnagels WHL, van Haelst UJGM et al. Methotrexate maintenance therapy and liver damage. Clin Exp Dermatol 1985; 10:194-200.
18. Miller JA, Dodd H, Rustin MHA et al. Ultrasound as a screening procedure for methotrexate-induced hepatic damage in severe psoriasis. Br J Dermatol 1985; 113:699-705.
19. Newman M, Auerbach R, Feiner H et al. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment. Arch Dermatol 1989; 125:1218-24.
20. Roenigk H, Auerbach R, Maibach HI et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38: 478-85.
21. Piccinino F, Sagnelli E, Pasquale G et al. Complications following percutaneous liver biopsy: a multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2:165-73.
22. Chalmers RJG, Kirby B, Smith A et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health care economic analysis. Br J Dermatol 2005; 152:444-500.
23. Ranganathan P, Eisen S, Yokoyama WM, McLeod HL. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis 2003; 62:4-9.
24. Grosflam J, Weinblatt ME. Methotrexate: mechanism of action, pharmacokinetics, clinical indications and toxicity. Curr Opin Rheumatol 1991; 3:363-8.
25. Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol Ther 1985; 28:77-102.
26. van Ede AE, Laan RF, Blom HJ et al. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998; 27:277-92.
27. Szeto DW, Cheng YC, Rosowsky A et al. Human thymidylate synthase. III. Effects of methotrexate and folate analogs. Biochem Pharmacol 1979; 28:2633-7.
28. Chabner BA, Allegra CJ, Curt GA et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 1985; 76:907-12.
29. Kremer JM. Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999; 29:14-26.
30. Ueland PM. Phamacological and biochemical aspects of S- adenosylhomocysteine and S-adenosylhomocysteine hydrolase. Pharmacol Rev 1982; 34:223-53.
31. Chen Z, Karaplis AC, Ackerman SL et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 2001; 10:433-43.
32. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356:1667-71.
33. Rozen R. Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis 1996; 19:589-94.
34. Engbersen AMT, Franken DG, Boers GHJ et al. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56:142-50.
35. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111-13.
36. Kang SS, Zhou J, Wong PW et al. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43:414-21.
37. van Ede AE, Laan RF, Blom HJ et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001; 11:2525-30.
38. Gabreels F, Stevens EM, Smeitink JA et al. A second common mutation in methylenetetrahydrofolate reductase gene: an additional risk factor for neural tube defects? Am J Hum Genet 1998; 62:1044-5.
39. Winegrad S, Weisberg I. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Circ Res 1998; 83:60-72.
40. Urano W, Taniguchi A, Yamanaka H et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002; 12:183-90.
41. Rady P, Szues S, Grady J et al. Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet 2002; 107:162-8.
42. Horie N, Aiba H, Oguro K et al. Functional analysis and DNA polymorphism of tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20:191-7.
43. Kumagai K, Hiyama K, Oyama T. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003; 11:593-600.
44. Kirby B, Lyon CC, Griffiths CE, Chalmers RJ. The use of folic acid supplementation in psoriasis patients receiving methotrexate; a survey in the United Kingdom. Clin Exp Dermatol 2000; 25: 265-8.
45. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991; 90:711-16.
46. Zachariae H, Sogaard H. Liver biopsy in psoriasis, a controlled study. Dermatologica 1983; 146:149-55.
47. Kuehl P, Zhang J, Lu Y et al. Sequence diversity in CYP 3A promoters and characterisation of the genetic basis of polymorphic CYP 3A5 expression. Nat Genet 2001; 27:383-91.
48. Ozdemir V, Kalowa W, Tang BK et al. Evaluation of the genetic component of variability in CYP 3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10:373-88.
49. Hesselink DA, van Schaik RH, van der Heiden EP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74:245-54.
50. Black AJ, McLeod HL, Capell HA et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129:716-18.
51. Evans WE, Hon YY, Bomgaars L et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19:2293-301.